Farnesoid X receptor (FXR)

Upregulation of microRNA-23b-3p induced by farnesoid X receptor regulates the proliferation and apoptosis of osteosarcoma cells
9

Inhibitory Effects of Bile Acids and Synthetic Farnesoid X Receptor Agonists on Rotavirus Replication
8

Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra and extrahepatic cholestasis
11

Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis
13

Farnesoid X receptor is essential for normal glucose homeostasis
9

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
9

Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
18

Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
17

Effective fecal microbiota transplantation for recurrent Clostridioides difficile infection in humans is associated with increased signalling in bile acid farnesoid X receptor fibroblast growth factor pathway
28

Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
13

Farnesoid X receptor agonists attenuate colonic epithelial secretory function and prevent experimental diarrhoea in vivo
10

Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential
33

TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells
6

Farnesoid X Receptor and Its Ligands Inhibit the Function of Platelets
28

Farnesoid X receptor represses hepatic human APOA gene expression
12

Treatment of mouse liver slices with cholestatic hepatotoxicants results in down-regulation of Fxr and its target genes
18

The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines
15

<p>Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data</p>
9

Current therapies in alleviating liver disorders and cancers with a special focus on the potential of vitamin D
18

Association of genetic variation in the NR1H4 gene, encoding the nuclear bile acid receptor FXR, with inflammatory bowel disease
12